Crosstalk between CML cells with HUVECs and BMSCs through exosomes
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by presence of the BCR-ABL fusion gene which encodes the constitutively active BCR-ABL chimeric protein. Imatinib is first FDA approved first-line BCR-ABL targeting drug for the treatment of newly diagnosed CML cases. Nowa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2020-10-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/26/3/10.2741/4901 |